Cargando…

Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained response

The widespread use of high‐dose therapy and autologous stem cell transplantation (ASCT) as well as the introduction of novel agents have significantly improved outcomes in multiple myeloma (MM) enabling long‐term survival. We here analyze factors influencing survival in 865 newly diagnosed MM patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lehners, Nicola, Becker, Natalia, Benner, Axel, Pritsch, Maria, Löpprich, Martin, Mai, Elias Karl, Hillengass, Jens, Goldschmidt, Hartmut, Raab, Marc‐Steffen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806105/ https://www.ncbi.nlm.nih.gov/pubmed/29282899 http://dx.doi.org/10.1002/cam4.1283

Ejemplares similares

A systematic classification of death causes in multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2018)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation
por: Merz, Maximilian, et al.
Publicado: (2017)

High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting
por: Lisenko, Katharina, et al.
Publicado: (2017)

Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma
por: John, Lukas, et al.
Publicado: (2023)

Association of resilience with health-related quality of life and depression in multiple myeloma and its precursors: results of a German cross-sectional study
por: Maatouk, Imad, et al.
Publicado: (2018)

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
por: Kriegsmann, Katharina, et al.
Publicado: (2019)

Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma
por: Maatouk, Imad, et al.
Publicado: (2019)

Can (18)F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?
por: Sachpekidis, Christos, et al.
Publicado: (2020)

Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
por: Klein, Eva-Maria, et al.
Publicado: (2021)

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma
por: Merz, Maximilian, et al.
Publicado: (2019)

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2016)

Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology—Highlights of the 8th Heidelberg Myeloma Workshop
por: Lutz, Raphael, et al.
Publicado: (2021)

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
por: Salwender, Hans, et al.
Publicado: (2019)

Novel immunotherapies in multiple myeloma – chances and challenges
por: Rasche, Leo, et al.
Publicado: (2021)

Complete response after autologous stem cell transplant in multiple myeloma
por: Kumar, Lalit, et al.
Publicado: (2014)

Which patients to sample in clinical cohort studies when the number of events is high and measurement of additional markers is constrained by limited resources
por: Edelmann, Dominic, et al.
Publicado: (2020)

Physical Activity in Multiple Myeloma: A Review of the Current Literature
por: Hillengass, Michaela, et al.
Publicado: (2023)

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2023)

Incidence and risk factors for acute kidney injury following autologous stem cell transplantation for multiple myeloma
por: Andronesi, Andreea G., et al.
Publicado: (2019)

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
por: Xu, J, et al.
Publicado: (2017)

Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation
por: Mosebach, Jennifer, et al.
Publicado: (2018)

miRNAs in multiple myeloma – a survival relevant complex regulator of gene expression
por: Seckinger, Anja, et al.
Publicado: (2015)

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial
por: Weisel, Katja C., et al.
Publicado: (2019)

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
por: Mai, Elias K., et al.
Publicado: (2020)

Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation—Results from the LenaMain Trial (NCT00891384)
por: Boquoi, Amelie, et al.
Publicado: (2023)

Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement
por: Lehners, Nicola, et al.
Publicado: (2017)

Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
por: Mai, Elias K., et al.
Publicado: (2021)

Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial
por: GroΔ, Jonathan P., et al.
Publicado: (2017)

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial
por: Klein, Eva-Maria, et al.
Publicado: (2021)

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials
por: Kauer, Joseph, et al.
Publicado: (2023)

Aspirin use and bleeding events during thrombocytopenia after autologous stem-cell transplantation for multiple myeloma
por: Neuendorff, Nina Rosa, et al.
Publicado: (2023)

The prognostic significance of [(18)F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
por: Gu, Jingli, et al.
Publicado: (2021)

Future Directions in Maintenance Therapy in Multiple Myeloma
por: Holstein, Sarah A., et al.
Publicado: (2021)

Selective elimination of immunosuppressive T cells in patients with multiple myeloma
por: Awwad, Mohamed H. S., et al.
Publicado: (2021)

Portrait of an autologous cancer vaccine: Then and now
por: Berd, David
Publicado: (2023)

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance
por: Seckinger, Anja, et al.
Publicado: (2018)

Epstein–Barr virus infection is associated with clinical characteristics and poor prognosis of multiple myeloma
por: Xia, Bing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6l39cjrfqtduu14c4vhkut7i9d